Rapamycin dosage

Protocol

1. 1

   Measure the dose

   Typical Rapamycin dose is 6 mg. Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer weekly (longevity protocols); daily for transplant indication. Half-life of 62 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   Longevity protocols commonly run weekly dosing with occasional planned washouts; no consensus on optimal duration

   Open tool →
4. 4

   Monitor for side effects

   Watch for: mouth ulcers (stomatitis); acne-like rash; GI upset; altered lipid panel. Stop or reduce dose if tolerability breaks down.

Why this dose

Binds FKBP12, and the resulting complex inhibits mTORC1, reducing protein synthesis and autophagy suppression downstream of nutrient and growth-factor signaling.

The typical 6 mg dose is the figure most commonly used in published protocols for Rapamycin. Treat the label as a starting point: body weight, training status, sleep, diet, and concurrent medications all shift the effective dose-response curve in real users.

How to administer

Rapamycin is administered via the oral route. Oral dosing is straightforward: take with water, with or without food unless specifically noted.

Onset of action runs around 1 hour after administration. Peak effect lands near 2 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Terminal half-life ~62 hours in healthy adults; supports weekly dosing for longevity protocols

Cycling and tolerance

Longevity protocols commonly run weekly dosing with occasional planned washouts; no consensus on optimal duration

Effects to expect at typical dose

• Inhibits mTORC1 signaling by binding FKBP12, reducing protein synthesis and relieving autophagy suppression
• ITP mouse program reproduced lifespan extension of ~10 to 25% across multiple genetic backgrounds and sexes
• Mannick trials showed improved influenza vaccine response in elderly adults using analogs of rapamycin
• PEARL human trial reported acceptable safety at 5 to 10 mg weekly with some functional and lean-mass signals
• Common dose-limiting adverse effects include stomatitis, acne-like rash, and mildly elevated lipid markers
• CYP3A4 substrate: grapefruit, ketoconazole, and clarithromycin substantially raise rapamycin exposure

Side effects and interactions

Common side effects

• mouth ulcers (stomatitis)
• acne-like rash
• GI upset
• altered lipid panel
• delayed wound healing

Notable interactions

• strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit) (major): substantially raises rapamycin levels, toxicity risk
• strong CYP3A4 inducers (rifampin, St John's wort) (major): lowers rapamycin levels, reduced effect
• live vaccines (major): reduced vaccine efficacy due to immunosuppression
• ACE inhibitors (moderate): increased risk of angioedema

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Rapamycin profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

allowed

DEA / Rx

Rx only (not a controlled substance)

Pregnancy

Not recommended

Legal status

Prescription only (off-label for longevity)

Do not use if

• active infection
• severe hepatic impairment
• planned surgery (delayed wound healing)
• pregnancy
• live vaccines within dosing window

Related research